Jeonjinbio전진바이오팜
110020 · KOSDAQ · ₩110020 · 전진바이오팜
₩2,050 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩14B | ₩19B | ₩16B | ₩7.8B | ₩3.2B |
| Cost of sales | ₩9.9B | ₩13B | ₩11B | ₩5.8B | ₩1.9B |
| Gross profit | ₩3.8B | ₩6.1B | ₩4.9B | ₩2B | ₩1.4B |
| Operating income | −₩343M | ₩1.2B | −₩1.2B | −₩3.2B | −₩3B |
| Net income | −₩196M | ₩4.3B | −₩6.4B | −₩3.2B | −₩2.1B |
| Net income to shareholders | −₩196M | ₩4.3B | −₩6.4B | −₩3.2B | −₩2.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩19B | ₩19B | ₩18B | ₩18B | ₩25B |
| Current assets | ₩9.5B | ₩10B | ₩7.8B | ₩4.7B | ₩16B |
| Cash and equivalents | ₩6.4B | ₩6.3B | ₩1.7B | ₩1.3B | ₩15B |
| Total liabilities | ₩1.1B | ₩1.2B | ₩11B | ₩8.4B | ₩14B |
| Current liabilities | ₩875M | ₩1.1B | ₩11B | ₩7.9B | ₩14B |
| Borrowings | ₩0 | ₩0 | ₩9.1B | ₩6B | ₩13B |
| Total equity | ₩17B | ₩18B | ₩6.2B | ₩9.5B | ₩11B |
| Shareholders' equity | ₩17B | ₩18B | ₩6.2B | ₩9.5B | ₩11B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩483M | ₩3B | −₩301M | −₩3.7B | −₩2.4B |
| Capital spending | ₩789M | ₩389M | ₩660M | ₩2B | ₩1.8B |
| Free cash flow | −₩306M | ₩2.6B | −₩961M | −₩5.7B | −₩4.2B |
Consolidated where available. Amounts in won.
Also known as: Jeonjinbio / 전진바이오팜 / 110020 / KRX:110020
Source: KRX statistical information